Your browser doesn't support javascript.
Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
Higgins, Renee L; Rawlings, Stephen A; Case, Jamie; Lee, Florence Y; Chan, Clarence W; Barrick, Bethany; Burger, Zoe C; Yeo, Kiang-Teck J; Marrinucci, Dena.
  • Higgins RL; Truvian Sciences, San Diego, California, United States of America.
  • Rawlings SA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, United States of America.
  • Case J; Scripps Clinic Bio-Repository and Bio-Informatics Core, La Jolla, California, United States of America.
  • Lee FY; Truvian Sciences, San Diego, California, United States of America.
  • Chan CW; Department of Pathology, University of Chicago, Chicago, Illinois, United States of America.
  • Barrick B; Scripps Clinic Bio-Repository and Bio-Informatics Core, La Jolla, California, United States of America.
  • Burger ZC; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, United States of America.
  • Yeo KJ; Department of Pathology, University of Chicago, Chicago, Illinois, United States of America.
  • Marrinucci D; Truvian Sciences, San Diego, California, United States of America.
PLoS One ; 16(3): e0247797, 2021.
Article in English | MEDLINE | ID: covidwho-1605332
ABSTRACT
Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body's temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31-60 days PSO. By 61-90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1-4 days PSO with 86% positivity observed at 5-7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0247797

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0247797